C88.80 Other malignant immunoproliferative diseases not having achieved remission

✓ Billable ICD-10-CM 2026
Open C88.80 in the app →

Get what a quick lookup can't: the AI assistant for official-guideline questions, HCC risk-adjustment mappings (CMS-HCC V24/V28, RxHCC), FDA drug indications, and AHA Coding Clinic references for C88.80.

The ICD-10-CM code for Other malignant immunoproliferative diseases not having achieved remission is C88.80 (FY2026). It is a billable, claim-ready diagnosis code.

Classification

Section
C81-C96: Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
Category C88
19 codes (12 billable)
FY2026 Status
Introduced in FY2025

Inclusion Terms

  • Other malignant immunoproliferative diseases NOS
  • Other malignant immunoproliferative diseases with failed remission

Official Coding Guidelines

Tx of primary site (TOC entry)

a. Admission/Encounter for treatment of primary site ............................................................. 33

— ICD-10-CM Official Guidelines for Coding and Reporting, FY2026, Section I.C.2.a
Tx of secondary site (TOC entry)

b. Admission/Encounter for treatment of secondary site .......................................................... 33

— ICD-10-CM Official Guidelines for Coding and Reporting, FY2026, Section I.C.2.b

Source: CMS — ICD-10-CM Official Guidelines for Coding and Reporting, FY2026

References

Cite This Page

Reference C88.80 with the canonical source and edition:

C88.80 — Other malignant immunoproliferative diseases not having achieved remission. ICD-10 Coding Pro (ICD-10-CM FY2026). https://icd10codingpro.com/codes/C88.80

Canonical URL: https://icd10codingpro.com/codes/C88.80

Related Codes

Search all 70,000+ ICD-10-CM codes →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2025-10-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial